Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

首次发布于 2023 年 3 月 8 日

Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

计划入组 40 人 · 首次发布于 2022 年 8 月 5 日

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

计划入组 141 人 · 首次发布于 2021 年 3 月 1 日

RAF-709

IKH-02

RAF-265

C₂₄H₁₆F₆N₆O

Tai Pan Vacation Inc.

Canada

PAN-MALAYAN PHARMACEUTICALS PTE LTD

Singapore

PURE & NATURAL HEALTH PTY LTD

Australia

Day One Biopharmaceuticals Advances FIREFLY-2 Trial and Reports Progress in DAY301 Study

FORE Biotherapeutics Advances Plixorafenib in BRAF-Driven Tumors, Eyes Potential FDA Submission

Leap Therapeutics Halves Workforce and Refocuses Cancer Drug Development Amid Market Challenges